<DOC>
	<DOCNO>NCT00337727</DOCNO>
	<brief_summary>The study test aprepitant prevention CINV patient receive initial cycle Moderately Emetogenic Chemotherapy ( MEC ) . Patients receive one cycle chemotherapy may opt participate optional second cycle patient receive antiemetic regimen cycle 1 , except IV formulation aprepitant give place oral formulation study day one . Study drug administration subsequent day give orally cycle 1 .</brief_summary>
	<brief_title>Aprepitant Prevention Chemotherapy Induced Nausea Vomiting ( CINV ) ( 0869-130 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients naive emetogenic chemotherapy histologically cytologically confirm malignant disease schedule receive single dose moderately emetogenic chemotherapy study day 1 Karnofsky score 60 great Patient schedule receive dose cisplatin Patient receive abdominal pelvic radiation week prior 6 day initiation chemotherapy Any allergy study drug antiemetic Taking CYP3A4 substrates/prohibited medication Significant medical mental condition Abnormal laboratory value ( platelet , absolute neutrophil , AST , ALT , bilirubin creatinine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>